Definitive Contract 75N93020C00017
Award Date
7/1/20
Potential Completion Date
12/31/22
Potential Value
$16M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Entasis Therapeutics Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Waltham, MA 02451, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This is a $27,032,719.27 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Spero Therapeutics, Inc. to advance the clinical and non-clinical development of an antibiotic candidate. The contract is not set aside. The contract originated from a NIAID Broad Agency Announcement (BAA) soliciting proposals for the advanced development of vaccine candidates, therapeutic products, and diagnostics to address biodefense, antimicrobial...
<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9,391,175.98 cost-plus-fixed-fee contract to Spero Therapeutics, Inc. to develop a second-generation polymyxin for the treatment of multidrug-resistant (MDR) Gram-negative infections. The contract, which does not have a set-aside designation, has a period of performance through June 15, 2021. Spero Therapeutics, Inc. is a for-profit organization based in Cambridge, Massachusetts.</p>
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $18,523,063 definitive cost-plus-fixed-fee contract to Blacksmith Medicines, Inc. (also doing business as Forge Therapeutics) to develop an LPXC inhibitor for the treatment of multidrug-resistant gram-negative urinary tract infections. This work will be performed in San Diego, California over 14 months. There is no set-aside designation associated with this contract....
<p>This is a $4,733,100.62 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Achaogen, Inc. for the development of "NOVEL LPXC INHIBITORS FOR THE TREATMENT OF CATEGORY A, B, AND C BACTERIAL INFECTIONS". The contract does not have a set-aside designation. The work is being performed in South San Francisco, California and the contract has an ultimate completion date of June 14, 2022.</p>
This is a $44,247,749 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Venatorx Pharmaceuticals Inc. (doing business as Venatorx) for the development of a novel beta-lactamase inhibitor targeting multidrug-resistant Acinetobacter baumannii. This contract is not set aside and was awarded through full and open competition. Venatorx is a biopharmaceutical company...
This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services (HHS), to Elusys Therapeutics Inc. The contract, valued at $13,853,653.00, is for biomedical research and development services, ranging from basic to advanced capabilities. The contract is a Definitive Contract with a Cost No Fee pricing type, and does not have a set-aside designation. The period of performance runs from September 28,...
This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...
This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for "Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens" and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.
This is a definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Spero Therapeutics, Inc. for the advanced research and development of SPR994, an oral carbapenem antibiotic to treat drug-resistant Gram-negative bacterial infections. The $43,372,809.00 cost-sharing contract has a period of performance through December 31, 2025. The contract was not set aside and originated from a Broad Agency Announcement (BAA) seeking proposals to develop...